

# MelNet update

20 September 2022

---

## Quality Statements to Guide Melanoma Diagnosis and Treatment in NZ

Second edition to be released shortly

The first review of the [Quality Statements](#) is almost complete, with the updated document anticipated to be uploaded to the MelNet website by the end of this month. MelNet members will be notified by email when it is available.

MelNet would like to thank the National Melanoma Working Group for their time and efforts, and everybody who provided feedback.

### Join the MelNet webinar series

To support the launch of the second edition of the Quality Statements, MelNet is excited to announce it will be hosting a six-part webinar series to help improve and build consistency in understanding of best practice melanoma management across the country. The webinars will step through each of the quality statements and associated good practice points, provide examples of their application to practice, highlight significant changes made during the 2022 review and provide you the opportunity to ask questions.

Each webinar is scheduled to take place on Thursday evening with a 7.00 pm start (**subject to change**):

27 October 2022	Webinar #1	<i>Prevention, early detection and diagnosis</i>
3 November 2022	Webinar #2	<i>Pathology and reporting</i>
10 November 2022	Webinar #3	<i>Staging, surveillance and follow up</i>
17 November 2022	Webinar #4	<i>Surgical management</i>
24 November 2022	Webinar #5	<i>Management of advanced melanoma</i>
1 December 2022	Webinar #6	<i>Multi-disciplinary &amp; coordinated care throughout the patient journey</i>

All healthcare professionals working in skin cancer management are warmly invited to attend. Keep an eye on your inbox for more information on how to register.

CME endorsement for this series is being sought from RNZCGP and RACS.

---

## Dermoscopy made easy | Online course to be held 12 November

Are you keen to get into dermoscopy?

Join Adjunct Associate Professor Amanda Oakley in her online '***Dermoscopy made easy***' course.

This beginner course will provide an overview the common elements of dermatoscopy and the clinical and dermatoscopic characteristics of benign and malignant lesions.

Information how to register will be available soon. In the meantime, make sure to block Saturday, **12 November 2022** from **8.00 am – 12.30 pm** in your diary.

CME endorsement for this course is being sought from RNZCGP and RACS.



## Notice of MelNet AGM | 12.30 pm, Friday 4 November 2022

The MelNet AGM will be held via Zoom from 12.30 – 1.00 pm on **Friday 4 November 2022**, immediately following a meeting of the Melanoma Research and Therapy Special Interest Group.

Members are invited to submit nominations for the Executive Committee in writing to the [MelNet Chief Executive](#) no later than 5.00 pm Friday 21 October 2022. These should include the nominee's name, a brief biography and the signatures of two members.

According to the MelNet rules, the Committee shall comprise at least eight and no more than ten members, with occupations that span the continuum. Members who will be serving the second year of their two-year term have surgical, oncological and primary prevention experience. Up to five additional members can be elected to the committee at the AGM. Preference will be given to those with expertise in general practice, nursing, pathology, dermatology and research.

All members are also invited to submit any remits or other matters to be considered at the AGM to the [MelNet Chief Executive](#) no later than 5.00pm Friday 21 October 2022.

[RSVP to attend the AGM](#)

---

## Melanoma Research and Therapy Special Interest Group meeting | Save the date

10.00 am – 12.30 pm

Friday 4 November 2022

Via Zoom

More details to follow.

---

## New sunscreen safety standard | In force from 8 September 2022

Earlier this year the [Sunscreen \(Product Safety Standard\) Act](#) was passed through Parliament. The purpose of this Act is to mandate a sunscreen product safety standard (the Standard). The Australian and New Zealand standard for sunscreen, AS/NZ 2604/2012, will be mandatory under the Fair Trading Act.

### Key details to be aware of:

- The Standard came into force on 8 September 2022.
- Any sunscreen product manufactured or imported after 8 March 2022 needs to be compliant with the Standard. A sunscreen product cannot be sold if it does not meet the Standard's requirements.
- The Standard allows for sunscreen products manufactured or imported to Aotearoa New Zealand before 8 March 2022 to be supplied until 8 September 2023.

The new Standard will give New Zealanders greater confidence in sunscreen product claims. The Commerce Commission is responsible for enforcing the Standard's provisions.

The implementation of the new Standard received media attention from several outlets: [Newshub](#), [TVNZ](#), [RNZ](#) and the [AM Show](#) (to name a few).

If you have questions about the new Standard, please email [sunscreen@comcom.govt.nz](mailto:sunscreen@comcom.govt.nz).

---

## Minimum standard of care for treatment of melanoma | Radio NZ interview with Dr Chris Boberg

MelNet Executive Co-Chair Dr Chris Boberg recently did an interview on Radio NZ highlighting the importance of the Quality Statements and reinforcing key messages about skin cancer prevention and early detection. He also gave an overview of MelNet and the important work we do.

[Listen to the interview](#)

---

## Skin Cancer Prevention webinar recording

MelNet Executive Committee member Dr Bronwen McNoe recently presented a webinar on the primary prevention of skin cancer. The talk outlined her research projects and how they have been used to support the Cancer Society's advocacy for improved prevention with sporting organisations, local government, and in educational settings.

[Watch the recording](#)

Should you have any issues with accessing the recording, please email [rana.peniamina@otago.ac.nz](mailto:rana.peniamina@otago.ac.nz).

## Get Spotted: Melanoma Awareness Campaign | Get involved in Melanoma New Zealand's annual awareness campaign

25 - 31 October 2022 (or another date that works for you)

Encourage your team, patients and community to have fun while raising awareness of the importance of skin checks and early detection.

1. [Register your support](#)
2. Hold your 'Get Spotted' event or fundraiser. You could dress up or decorate your practice in spots, run a special Melanoma Awareness Campaign skin check offer in support of the cause, or any other support you can offer that helps spread awareness.



To raise even more awareness, follow Melanoma New Zealand on [Facebook](#), [Twitter](#), [Instagram](#) and/or [LinkedIn](#) and share their Get Spotted content. You can also upload photos or videos of your "Get Spotted" activities to your social channels - don't forget to tag @Melanoma New Zealand with the hashtags #GetSpotted #CheckYourSkin

Thank you for your support.

## Upcoming opportunities and events



The 18<sup>th</sup> World Congress on Cancers of the Skin, scheduled from 26 – 29 October 2022, is hosted in Buenos Aires, Argentina, and online. Colleagues interested in the basic science, prevention and treatment of melanoma and non-melanoma skin cancer will benefit from important content for clinical practice and research.

[More information](#)   [Programme](#)   [Register now](#)

## Other upcoming opportunities and events

October
<b>Professional Certificate of Skin Cancer Medicine</b> <b>Professional Certificate of Skin Cancer Surgery</b> <b>Advanced Certificate of Skin Cancer Surgery</b> <b>8 October 2022</b> Melbourne, Australia <a href="#">Find out more</a>
<b>Advanced Certificate of Skin Cancer Medicine</b> <b>Professional Diploma of Skin Cancer Surgery</b> <b>9 October 2022</b> Melbourne, Australia <a href="#">Find out more</a>
<b>19<sup>th</sup> International Congress of the Society for Melanoma Research</b>

November
<b>The 3rd Immuno-Oncology World Congress (Immuno-Oncology2022)</b> <b>2 – 3 November 2022</b> Copenhagen, Denmark <a href="#">Find out more</a>
<b>Clinical Oncology Society of Australia (COSA's) 49th Annual Scientific Meeting</b> <b>2 - 4 November 2022</b> Brisbane, Australia <a href="#">Further information</a>
<b>37<sup>th</sup> Annual Meeting &amp; Pre-Conference Programs (SITC 2022)</b> <b>8 – 12 November 2022 (ET)</b>

**17 – 20 October 2022**

Edinburgh, Scotland

[Further information](#)

**Spotlight on clinical trials: Understanding your patients' needs (MIA Nurse Webinar Series)**

**18 October 2022**

Online

[Further information](#)

**Certificate of Dermoscopy - Online**

**21 October - 2 December 2022**

Online

[Find out more](#)

**Certificate of Skin Cancer Medicine**

**22 - 23 October 2022**

Melbourne

[Find out more](#)

**Advanced Skin Surgery Workshop**

**28 - 31 October 2022**

Sydney

[Find out more](#)

Boston, USA

[Find out more](#)

**Certificate of Skin Cancer Medicine**

**19 - 20 November 2022**

Auckland

[Find out more](#)

**Professional Certificate of Skin Cancer Medicine**

**Professional Certificate of Skin Cancer Surgery**

**19 November 2022**

Perth, Australia

[Find out more](#)

**Advanced Certificate of Skin Cancer Medicine**

**Professional Diploma of Skin Cancer Surgery**

**20 November 2022**

Perth, Australia

[Find out more](#)

[For more events see the MelNet events calendar](#)

## Recent MelNet website postings

Below is a selection of recent **news postings** on the MelNet website. Please visit the [website](#) to view all the latest news items.

[Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors](#)

[Tumor-infiltrating lymphocytes are robust prognostic markers in patients with primary melanoma](#)

[Review of literature: The role and indications for radiation therapy in patients with non-melanoma skin cancer](#)

[Circulating tumour cells are a unique potential tool to guide treatment strategies in advanced disease melanoma patients](#)

[Assessment of melanoma thickness based on dermoscopy images by readers and convolutional neural networks](#)

[Identification of high-risk sentinel node positive AJCC stage IIIA patients who are more likely to derive benefit from adjuvant systemic therapy](#)

[Disease burden attributable to non-melanoma skin cancer will continue to increase or remain stable at high levels](#)



Support our work. Donate to MelNet



Join us on facebook